Estrategias de tratamiento en tumores Neuroendocrinos: desde análogos de Somatostatina hasta la terapia con Radionúclidos

TARGETED AGENTS

CABOZANTINIB

RECIST RESPONSE PROFILE BY PRIOR THERAPY:

CARCINOID

Chan J, et al. J Clin Oncol 2017; 35, no. 4_suppl 228-228.

Median prior therapies: 1 (range 0-6)

Median PFS: 31.4 months (8.5-NR months)